Material Event Form 8 K

Item 8.01 Other Events

On October 21, 2024, Trevi Therapeutics, Inc. (the "Company") announced that enrollment has been completed in the Company's Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of refractory chronic cough and the Company expects to report topline data in the first quarter of 2025.

Forward-Looking Statements

Statements contained in this current report on Form 8-K regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's expectation of reporting topline data from the Company's Phase 2a RIVER trial in the first quarter of 2025. Risks that contribute to the uncertain nature of the forward-looking statements include uncertainties regarding the success and timing of the Company's product candidate development activities, including its ongoing clinical trials, uncertainties regarding the Company's ability to execute on its strategy, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this current report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.